<DOC>
	<DOCNO>NCT00672464</DOCNO>
	<brief_summary>Primary Objective : To compare added metformin and/or add simvastatin versus intervention reduce eliminate increase cardiovascular risk ( estimate elevation non-HDL cholesterol level ) treatment schizophrenia olanzapine . Secondary Objective ( ) : To compare added metformin and/or add simvastatin versus intervention reduce eliminate increase cardiovascular risk ( estimate elevation triglyceride level ) treatment schizophrenia olanzapine . To compare added metformin and/or add simvastatin versus intervention reduce eliminate increase cardiovascular risk ( estimate C-reactive protein level ) treatment schizophrenia olanzapine</brief_summary>
	<brief_title>Cardio Risk Acute Schizophrenia Olanzapine Duke</brief_title>
	<detailed_description>Olanzapine offer great therapeutic antipsychotic benefit non-clozapine antipsychotic medication available U.S. , make desirable choice long-term maintenance treatment patient schizophrenia ( Lieberman et al , 2005 ) . Long-term compliance efficacious antipsychotic medication fundamental optimal therapeutic outcome . Toward goal , long-acting injectable preparation olanzapine soon available . However , long-term use olanzapine limit substantial , un-wanted effect metabolism result weight gain , increase insulin resistance , increase non-HDL-cholesterol , increase C-reactive protein ( Lieberman et al , 2005 ; McEvoy et al , 2005 ; Meyer et al , 2008 ; McEvoy et al , submission ) . Over long term , insulin resistance contributes accelerate incidence diabetes mellitus observe among patient schizophrenia since availability atypical antipsychotic medication ( Basu A , 2006 ) . Over long term , elevate non-HDL-cholesterol increased inflammation contribute independently accelerate cardiovascular mortality observe among patient schizophrenia since availability atypical antipsychotic medication ( Saha et al , 2007 , Capasso et al , 2007 ) . Inflammation , measure C-reactive protein , provide added , independent predictive value cardiovascular risk beyond measure insulin resistance elevate non-HDL-cholesterol . Established strategy exist may attenuate unwanted effect olanzapine metabolism inflammation . Metformin show reduce weight gain insulin resistance pre-diabetic , obese individual without mental problem ( Salpeper et al , 2008 ) patient treat atypical antipsychotic medication ( Wu et al , 2008 ) . Statins show reduce non-HDL-cholesterol cardiovascular morbidity mortality ( Lee et al , 2007 ) . Both metformin statin show reduce C-reactive protein ( Bulcau et al , 2007 ) . We propose implement pilot study estimate effect size ( change triglyceride , change non-HDL-cholesterol , change CRP ) add metformin , add simvastatin , add metformin simvastatin , versus add intervention 120 newly-admitted , acutely psychotic , recently un-medicated patient schizophrenia 4 week prospective treatment olanzapine . We also compare patient ( baseline value , recently medicate state ) 40 age , race , gender match control subject fast triglyceride , non-HDL-cholesterol , CRP level . We recruit newly admit patient experience acute psychotic relapse schizophrenia ( related failure take prescribe antipsychotic medication ) . After baseline assessment sampling complete , patient treat olanzapine zydis 15 mg QHS 28 day . All patient randomize 1:1:1:1 added metformin , add simvastatin , add metformin simvastatin , intervention . All treatment open label . Repeated assessment weight , non-HDL-cholesterol , triglycerides C-reactive protein obtain . Subjects remain inpatient JUH duration study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>We include patient come u free antipsychotic medication , i.e. , patient chronic schizophrenia ( least one prior psychiatric hospitalization ) antipsychotic medication least 3 week newly hospitalize treatment acute psychotic relapse ; patient male female , 1860 year age , meet DSMIV criterion schizophrenia , score &gt; =4 least two PANSS Positive subscale item . We exclude patient whose psychosis predominantly affective nature explainable basis substance abuse comorbid medical condition , patient diabetes mellitus , epilepsy , mental retardation , organic mental syndrome , patient currently take metformin statin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective</keyword>
	<keyword>Cardiovascular</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Metformin</keyword>
	<keyword>Simvastatin</keyword>
</DOC>